Allergy vaccines containing hybrid polypeptides

Details Allergy vaccines containing hybrid polypeptides Allergy vaccines containing hybrid polypeptides

2011-01-04

2011-01-04

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Allergen or component thereof

C424S001690, C424S009810, C424S178100, C424S184100, C424S185100, C424S192100, C424S278100, C435S004000, C435S041000, C435S069700, C436S513000

Reexamination Certificate

active

07862828

ABSTRACT:
Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.

REFERENCES:
patent: 5804201 (1998-09-01), King
patent: 5958415 (1999-09-01), Yuuki et al.
patent: 5968526 (1999-10-01), Garman et al.
patent: 6008340 (1999-12-01), Ball et al.
patent: WO 93/08280 (1992-10-01), None
patent: WO 95/34578 (1995-12-01), None
patent: WO 97/06263 (1996-08-01), None
patent: WO 97/07218 (1997-02-01), None
Vrtala et al. 1997. J. Cin. Invest. 99(7): 1673-1681.
Vrtala et al. 1996. J. All. Clin. Immun. 97:781-787.
Vrtala et al., (1996. J. Allergy Clin Immun. vol. 97(3):781-787).
Pauli, G., et al., “Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population,”Clinical and Experimental Allergy, 30: 1076-84 (2000).
Van Hage-Hamsten, M., et al., “Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season,”The Journal of Allergy and Clinical Immunology, 104: 969-77 (Nov. 1999).
Vrtala, S., et al., “Conversion of the Major Birch Pollen Allergen, Bet v 1, into Two Nonanaphylactic T Cell Epitope-containing Fragments,”J. Clin. Invest., 99:1673-1681 (Apr. 1997).
Vrtala, S., et al., “Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Ph1 p 1, Ph1 p 2, Ph1 p 5),”The Journal of Allergy and Clinical Immunology, 97: 781-87 (Mar. 1996).
Vrtala, S., et al., “Molecular, Immunological, and Structural Characterization of Phl p 6, a Major Allergen and P-Particle-Associated Protein from Timothy Grass (Phleum pratense) Pollen,”The Journal of Immunology, 163: 5489-96. (1999).
Mellerup, M.T., et al., “Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment,”Clinical and Experimental Allergy, 30: 1423-1429 (2000).
Noon, L., et al., Prophylactic Inoculation Against Hay Fever,The Lancet, 1572-1573 (Jun. 10, 1911).
Niederberger, V., et al., “IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE,”The Journal of Allergy and Clinical Immunology, 101: 258-64 (Feb. 1998).
Bousquet, J., et al., “Allergen immunotherapy: therapeutic vaccines for allergic diseases,”The Journal of Allergy and Clinical Immunology, 102: 558-62 (Oct. 1998).
Durham, S.R., et al., “Immunologic changes associated with allergen immunotherapy,”The Journal of Allergy and Clinical Immunology, 102: 157-64 (Aug. 1998).
Laffer, S., et al., “Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations,”The Journal of Allergy and Clinical Immunology, 98: 652-58 (Sep. 1996).
European Search Report, EP 01 13 0292.
B. Pandjaitan et al.; pET-Prof, A Plasmid for High-Level Expression of Recombinant Peptides Fused to a Birch Profilin-Derived Hexadecapeptide Tag: A System for the Detection and Presentation of Recombinant Antigens,Gene, 237(2): 333-342 (1999).
L. Zhang et al.; “Antigen- and Isotype-Specific Immune Responses to a Recombinant Antigen-Allergen Chimeric (RAAC) Protein”;Journal of Immunology, 151(2): 791-799 (1993).
B. Linhart et al.; “Genetically Engineered Hybrid Vaccines for the Treatment of Grass Pollen Allergy”,Journal of Allergy and Clinical Immunology, 107(2): S56 (2001-02).
F. Kussebi et al.; “A Novel Type of a Vaccine for Bee Venom Allergy Obtained by Gene Fusion of the Two Major Allergens”,Allergy, 56 (S68): 13 (2001).

Affiliated with

Also associated with

Rating

Allergy vaccines containing hybrid polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Allergy vaccines containing hybrid polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allergy vaccines containing hybrid polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2720812